Exchange: NASDAQ
Industry: Drug Manufacturers/Other
Last Trade: 4:00 PM ET 2/8/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.10 | -0.31 | 67.74 |
| EPS, GAAP | -0.10 | -0.31 | 67.74 |
| Consensus Estimate | -0.14 | -0.27 | 48.15 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | -0.74 | -1.10 | 32.73 |
| EPS, GAAP | -0.74 | -1.15 | 35.65 |
| Consensus Estimate | -0.84 | NA | NA |
| OREX | Industry Average | |
| P/E (TTM) | -4.22 | 29.40 |
| P/E (Forward) | NA | -4.30 |
| PEG Ratio | NA | -0.21 |
| Price/Sales | 33.93 | 4.56 |
| Beta | 1.77 | 1.78 |
| 1/11/2012 | Finding companies that have all the right stuff can produce winners. (The Motley Fool) |
| 1/9/2012 | VIVUS' news is great news. (The Motley Fool) |
| 1/4/2012 | Arena resubmits lorcaserin for FDA approval. (The Motley Fool) |
| 12/30/2011 | Arena ends the year on an upswing. (The Motley Fool) |
| 12/22/2011 | Qnexa data can't be ignored. (The Motley Fool) |
| 11/11/2011 | A quarterly profit shocks analysts and me alike. (The Motley Fool) |
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
![[sm0212texas]](http://s.wsj.net/public/resources/images/PF-AB841_sm0212_C_20120117123418.jpg)
